THiogenesiS THerapeuticS

From a De-Risked Late-Stage Rare Disease to a Platform in Cellular Energy and Health

(TSXV: TTI / OTCQX: TTIPF)

January - 2026

Forward Looking Statement

This document and any attachments are intended for information purposes only and should not be construed as on offer or solicitation for the sale of securities. Statements in this presentation include forward-looking statements within the meaning of certain securities laws. These forward-looking statements include, among others, statements with respect to our objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, objectives, expectations, anticipations, estimates and intentions. The words "expected to" "illustrate" "has the potential to" "will be", "evaluating" "plans" "can be" "planning" "to predict" "potential" "may" "should" and words and expressions of similar import, are intended to identify forward-looking statements.

Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not put undue reliance on these statement or the scientific data presented as a number of important factors, many of which are beyond our control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. We do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary language.

Thiogenesis – Leadership/Inception

Deep experience at the intersection of rare disease, mitochondrial biology and capital markets

Christopher M. Starr, PhD
Chairman of the Board

- Co-founder, BioMarin; co-founder & *CEO of Raptor (acquired for $800M → cystinosis)*

Patrice Rioux, MD, PhD
Founder, CEO, Director

- Leading authority in orphan drug development and mitochondrial metabolism
- Former CMO / Head of Regulatory at Raptor; *led approval of Procysbi® (delayed-release cysteamine)*

- **Procysbi® was studied in mitochondrial and related diseases** → *strong efficacy signals, GI side effects and dosing limitations halted progress*
- **Lead compound, TTI-0102** → *controlled-release cysteamine, well-tolerated at significantly higher doses in Phase 1 volunteer study*

BIOMARIN Biogen RepliGen raptor pharmaceutical corp. Naglazyme ALDURAZYME (LARONIDASE) KUVAN (sapropterin dihydrochloride) Tablets or Powder for Oral Solution PROCYSBI (cysteamine bitartrate) delayed-release capsules delayed-release oral granules

Thiogenesis – Investment Summary

Clinical-stage biotech developing cysteamine–based prodrugs for high-need pediatric and orphan diseases

- **Staged value-creation:** Late-stage de-risking with significant platform upside
- **De-risked anchor:** Clear Phase 3 pathway in cystinosis establishes a valuation floor
- **Platform upside:** Same biology applies across mitochondrial and pediatric metabolic diseases
- **Human validation:** Positive Phase 2 MELAS data supports the mechanism
- **Capital Efficient:** Major milestones achievable without significant expenditure
- **Near-term catalysts:** *Cystinosis investigator-initiated study and Leigh syndrome Phase 2*

Nephropathic Cystinosis

A de-risked, late-stage rare disease opportunity



- Rare genetic disorder characterized by the ***toxic buildup of cystine*** in lysosomes (the cell's digestive compartments)
- Requires lifelong therapy to deplete cystine
- Current cysteamine treatment is effective but limited by frequent dosing and gastrointestinal side effects
- **Upcoming:** Investigator-initiated confirmatory trial led by a top expert in cystinosis, scheduled for Q2 2026
- *Cysteamine boosts intracellular cysteine levels, which is the rate-limiting factor in glutathione synthesis, an antioxidant essential to the platform crossing over into mitochondrial disease*

Besouw M - Adapted from et al. Drug Discovery Today, 2013

The Platform & TTI-0102

Well-tolerated at 4x the therapeutic dose in human study

Phase 1 Study (PK/Safety)



- ***TTI-0102 is a cysteamine-based prodrug***
- **Prodrug** is an inactive compound that is slowly activated when metabolized – reduces side effects and increases bioavailability
- ***TTI-0102 designed to deliver:***
  - Improved tolerability via lower peak exposure, even at higher doses
  - Once-daily oral dosing
- ***505(b)(2) regulatory pathway*** reduces time & cost by avoiding redundant studies

Lysosomal & Mitochondrial Disease

Disease-specific in cystinosis and platform-wide benefits



MELAS

(Mitochondrial Encephalomyopathy, Lactic Acidosis & Stroke Like Episodes)

Clinical validation in mitochondrial disease (MELAS)

- Severe mitochondrial disease with no approved therapies
- **Phase 2 (EU) study showed:**
  - Statistically significant fatigue improvement
  - Once-daily dosing potential with improved tolerability
- Biomarker shifts consistent with improved cellular energy handling
- Data accepted as **late-breaking news** at major mitochondrial conference

Leigh Syndrome Spectrum (LSS)

Translating MELAS insights into a high-need pediatric indication

- Devastating pediatric mitochondrial disorder; no approved therapies
- FDA-cleared IND for a two-stage Phase 2a clinical trial, conducted in *collaboration with a global leader in pediatric mitochondrial medicine*
- **Trial design informed directly by MELAS:**
  - Weight-based dosing
  - Biomarkers
  - Functional endpoints (fatigue / MM-COAST)
- **Near-term catalyst:**
  - Trial initiation - March/April
  - Initial data – September/October

Scientific Advisory Board

World-class experts in mitochondrial, metabolic & lysosomal disease

Dr. David Housman

- MIT, award winning professor of biology, known for his contribution to the study of Huntington's disease and as a co-founder of 5 biotech companies

Dr. Gregory Enns

- Stanford University, professor of Medical Genetics and Director of Biochemical Genetics Program; focus on mitochondrial and lysosomal disorders

Dr. Miriam Vos

- Emory University, professor of Pediatrics and Division of Gastroenterology, Hepatology and Nutrition, and Director of Pediatric Fatty Liver Program at Children's Healthcare of Atlanta

Company Info

Thiogenesis Therapeutics	(TSXV: TTI / OTCQX: TTIPF)
Shares Issued	51.8 million
Shares Fully Diluted	56.9 million
Insiders (32%)	16.7 million
Share Price (01/15/2026)	$0.61
52 week high/low	$0.88/C$0.51
Market Cap.	$31.6 million
Cash (09/30/2025)	$3.3 million
Contact	info@thiogenesis.com

- Currency in Canadian dollars

Thiogenesis – Upcoming Milestones

Potential milestones (6 months):

Cystinosis	⟶	Investigator lead study H1-2026
Leigh syndrome	⟶	Phase 2a patient enrollment Q1-26/data Q3-26
MELAS	⟶	Phase 2 data Q1-26
Pediatric MASH	⟶	Phase 2 IMPD cleared 2026